Abraxane News and Research

RSS
The U.S. Food and Drug Administration approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Multiple presentations on nab-driven chemotherapy at 46th ASCO

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Saint John's Health Center Trustee receives 2010 Distinguished Medical Science Award

Saint John's Health Center Trustee receives 2010 Distinguished Medical Science Award

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

ABRAXANE accepted for restricted use within Scotland NHS

ABRAXANE accepted for restricted use within Scotland NHS

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

Genta reports net loss of $11.7M for fourth-quarter 2009

Genta reports net loss of $11.7M for fourth-quarter 2009

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

COTI's novel small molecule effective against pancreatic cancer in animal model

COTI's novel small molecule effective against pancreatic cancer in animal model

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

Phase II clinical trial results of Liposome-Entrapped Paclitaxel announced

Phase II clinical trial results of Liposome-Entrapped Paclitaxel announced

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

iRGD peptide found to enhance both cancer detection and treatment

iRGD peptide found to enhance both cancer detection and treatment

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Press conference highlights emerging treatments in pancreatic cancer

Press conference highlights emerging treatments in pancreatic cancer

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009